Cargando…
Management of Coronary Artery Spasm
Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standa...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345953/ https://www.ncbi.nlm.nih.gov/pubmed/37456765 http://dx.doi.org/10.15420/ecr.2022.47 |
_version_ | 1785073206237855744 |
---|---|
author | Lanza, Gaetano Antonio Shimokawa, Hiroaki |
author_facet | Lanza, Gaetano Antonio Shimokawa, Hiroaki |
author_sort | Lanza, Gaetano Antonio |
collection | PubMed |
description | Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standard treatments, several other alternative drugs and interventions have been proposed, including the Rho-kinase inhibitor fasudil, anti-adrenergic drugs, neural therapies and percutaneous coronary interventions. In patients with syncope or cardiac arrest caused by CAS-related tachyarrhythmias, or even bradyarrhythmias, implantation of an ICD or pacemaker, respectively, should be considered according to the risk of recurrence and efficacy of vasodilator therapy. |
format | Online Article Text |
id | pubmed-10345953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Radcliffe Cardiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-103459532023-07-15 Management of Coronary Artery Spasm Lanza, Gaetano Antonio Shimokawa, Hiroaki Eur Cardiol Ischaemic Heart Disease Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standard treatments, several other alternative drugs and interventions have been proposed, including the Rho-kinase inhibitor fasudil, anti-adrenergic drugs, neural therapies and percutaneous coronary interventions. In patients with syncope or cardiac arrest caused by CAS-related tachyarrhythmias, or even bradyarrhythmias, implantation of an ICD or pacemaker, respectively, should be considered according to the risk of recurrence and efficacy of vasodilator therapy. Radcliffe Cardiology 2023-05-22 /pmc/articles/PMC10345953/ /pubmed/37456765 http://dx.doi.org/10.15420/ecr.2022.47 Text en Copyright © 2023, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. |
spellingShingle | Ischaemic Heart Disease Lanza, Gaetano Antonio Shimokawa, Hiroaki Management of Coronary Artery Spasm |
title | Management of Coronary Artery Spasm |
title_full | Management of Coronary Artery Spasm |
title_fullStr | Management of Coronary Artery Spasm |
title_full_unstemmed | Management of Coronary Artery Spasm |
title_short | Management of Coronary Artery Spasm |
title_sort | management of coronary artery spasm |
topic | Ischaemic Heart Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345953/ https://www.ncbi.nlm.nih.gov/pubmed/37456765 http://dx.doi.org/10.15420/ecr.2022.47 |
work_keys_str_mv | AT lanzagaetanoantonio managementofcoronaryarteryspasm AT shimokawahiroaki managementofcoronaryarteryspasm |